公开(公告)号：US20220135638A1

公开(公告)日：2022-05-05

申请号：US17279266

申请日：2019-09-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hiroshi IMOTO ,  Mari ADACHI ,  Yoko KANEMATSU ,  Taiji ASAMI ,  Ayumu NIIDA ,  Naoki NISHIZAWA ,  Derek Cecil COLE ,  Mack FLINSPACH ,  Nick SCORAH ,  Abhijit Suresh BHAT

IPC: C07K14/575 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K9/20 ,  A61P1/08

Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.

公开(公告)号：US20210115048A1

公开(公告)日：2021-04-22

申请号：US16608723

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji KITAMURA ,  Zenichi IKEDA ,  Minoru IKOMA ,  Koji WATANABE ,  Hideki HIROSE ,  Takafumi YUKAWA ,  Sachie MORIMOTO ,  Naoki NISHIZAWA ,  Taiji ASAMI

IPC: C07D487/04 ,  A61P9/04 ,  A61K47/38 ,  A61K31/4184 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.